Aneurysm News and Research

RSS

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston.

19 Nov 2010

Genetic alterations may lead to thoracic aortic disease

19 Nov 2010

Study shows asthma drugs can treat aortic aneurysm

A new study from the Swedish medical university Karolinska Institutet shows that asthma drugs are a potential treatment for aortic aneurysm. These drugs, which block cysteinyl-leukotrienes, could reduce the break down of vessel wall tissue and the dilation of the aortic wall, and thus the risk of its rupturing.

16 Nov 2010

New catheter device for abdominal aortic aneurysm

William E. Sorfleet had a life-threatening abdominal aortic aneurysm, but at age 82, he was too old for major invasive surgery to repair the bulging blood vessel. So vascular surgeon Dr. Ross Milner of Loyola University Hospital repaired the aneurysm with a catheter device instead of a scalpel. The catheter, inserted through an artery, deployed a device called a stent graft that repaired the aneurysm.

12 Nov 2010

Researchers to determine levels of stroke risk in patients with narrowed brain arteries

Neurological researchers at Rush University Medical Center are part of a multicenter, National Institutes of Health (NIH) study to determine the levels of stroke risk and stroke recurrence in patients with narrowed brain arteries.

10 Nov 2010

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.

4 Nov 2010

Endologix implants Ventana stent graft for endovascular repair at Auckland City Hospital

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, announced today the first clinical implant of the Company's Ventana fenestrated stent graft at Auckland City Hospital in Auckland, New Zealand.

3 Nov 2010

FDA approves Medtronic Talent Thoracic Stent Graft with Captivia Delivery System

Advancing the minimally invasive treatment of aortic aneurysms, Medtronic, Inc. (NYSE: MDT), today announced approval by the U.S. Food and Drug Administration (FDA) of the Talent Thoracic Stent Graft with Captivia® Delivery System, which features a tip capture mechanism for controlled deployment and precise placement of the implantable medical device.

2 Nov 2010

Stryker enters agreement to acquire assets of Neurovascular division of Boston Scientific

Stryker Corporation announced today a definitive agreement to acquire the assets of the Neurovascular division of Boston Scientific in an all cash transaction for $1.5 billion, which includes $100 million of milestone payments.

From Stryker 29 Oct 2010

Monitoring glucose levels in brain can help predict second-wave of damage in head injury patients

Why do some of the one million people who sustain head injuries annually in United States experience a mysterious second wave of brain damage days after the initial injury - just when they appear to be recovering? Limited clinical trials using an innovative new device to monitor brain chemistry on a second-by-second basis are underway to answer that life-and-death question, according to an article in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine. Brain injury is the leading cause of death and disability worldwide.

28 Oct 2010

Endologix announces definitive agreement to acquire Nellix

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment of Abdominal Aortic Aneurysms (AAAs).

28 Oct 2010

Endologix 2010 third quarter total revenue increases 30% to $17.9 million

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2010.

28 Oct 2010

Columbia University researchers to use IBM's streaming analytics to detect complications in brain injury

IBM today announced a new project in which researchers at Columbia University Medical Center will utilize IBM's streaming analytics technology to potentially detect severe complications in brain injured patients up to 48 hours earlier than traditional methods.

27 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Annals of Vascular Surgery publishes Endologix's Powerlink System clinical trial results for AAA endovascular repair

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, announced today the publication of results from its pivotal, multicenter, prospective clinical trial of the Company's Powerlink System for endovascular repair of abdominal aortic aneurysm (AAA) using an anatomical fixation technique with a suprarenal aortic extension.

19 Oct 2010

New data on implementation of minimally invasive treatments for ruptured intracranial aneurysms

Two recent studies from the Zeenat Qureshi Stroke Research Center, in Minneapolis, MN, provide new data regarding implementation of minimally invasive treatments for ruptured intracranial aneurysms and impact on patient outcomes in U.S.

11 Oct 2010

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

W. L. Gore & Associates announced the treatment of the first European patients with the new 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, the longest length stent-graft available in Europe. Piotr Kasprzak, from the Department of Vascular Surgery at the Klinikum der Universität in Regensburg, Germany, and Thomas Zeller, MD, from the Department of Angiology at the Herz-Zentrum in Bad Krozingen, Germany successfully treated patients using the Gore device.

23 Sep 2010

Environmental factors are cause of subarachnoid haemorrhage in most cases

The Nordic twin study investigating the heritability of subarachnoid haemorrhage (SAH) suggests that the role of genetic factors underlying the development of SAH is less than previously believed.

20 Sep 2010

GORE C3 Delivery System enables repositioning of stent graft during procedure for AAA

W. L. Gore & Associates (Gore) today announced the first clinical uses of the GORE C3 Delivery System to deploy the GORE EXCLUDER AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

16 Sep 2010

Actress joins UTHealth to establish 'John Ritter Research Program in Aortic and Vascular Diseases'

Actress, writer and aortic health advocate Amy Yasbeck has joined with The University of Texas Health Science Center at Houston (UTHealth) to establish the John Ritter Research Program in Aortic and Vascular Diseases (JRRP) to combat the devastating disease that took the life of her husband, legendary comic actor John Ritter.

15 Sep 2010

Aneurysm News and Research

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Genetic alterations may lead to thoracic aortic disease

Study shows asthma drugs can treat aortic aneurysm

New catheter device for abdominal aortic aneurysm

Researchers to determine levels of stroke risk in patients with narrowed brain arteries

SurModics and Edge Therapeutics enter licensing agreement for drug delivery technology

Endologix implants Ventana stent graft for endovascular repair at Auckland City Hospital

FDA approves Medtronic Talent Thoracic Stent Graft with Captivia Delivery System

Stryker enters agreement to acquire assets of Neurovascular division of Boston Scientific

Monitoring glucose levels in brain can help predict second-wave of damage in head injury patients

Endologix announces definitive agreement to acquire Nellix

Endologix 2010 third quarter total revenue increases 30% to $17.9 million

Columbia University researchers to use IBM's streaming analytics to detect complications in brain injury

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

Annals of Vascular Surgery publishes Endologix's Powerlink System clinical trial results for AAA endovascular repair

New data on implementation of minimally invasive treatments for ruptured intracranial aneurysms

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

Environmental factors are cause of subarachnoid haemorrhage in most cases

GORE C3 Delivery System enables repositioning of stent graft during procedure for AAA

Actress joins UTHealth to establish 'John Ritter Research Program in Aortic and Vascular Diseases'

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News